medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2010, Number 3

<< Back Next >>

Arch Neurocien 2010; 15 (3)

Anisotropy fraction of the corpus callosum in multiple sclerosis and antiphospholipid syndrome

Bonifacio-Delgadillo D, Carrillo-Mezo D, García-Márquez A, Pérez RA, Flores RJJ

Language: Spanish
References: 42
Page: 134-138
PDF size: 227.53 Kb.


ABSTRACT

Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system that affects 3.6 per 100,000 population per year. The antiphospholipid syndrome (APL) is an autoimmune disease characterized by the presence of antiphospholipid antibodies and at least one clinical manifestation Both diseases have similar clinical manifestations and sometimes it is not possible to obtain a proper finding to differentiate them by MRI. In MS, the corpus callosum is a structure that is invariably affected, unlike APL in which there is no apparent involvement of the corpus callosum and therefore we expected to find differences in the fractional anisotropy (FA) measured in the corpus callosum of patients, thus providing another tool to aid in the differential diagnosis. Our study showed statistically significant differences in the FA of the corpus callosum of patients with MS (FA rating: 0.65122; DE: 0.07588, P = 0.006) and APL (FA rating: 0.66777; DE: 0.05715, P = 0.024 ), and in the control group (FA rating: 0.73222, DE: 0.03671). However, no difference was found between the group of patients with MS and the group of patients with APL (p = 0.334). This study contributes to the study of patients with APL as it showed that like in MS, a reduced corpus callosum FA is observed with respect to control subjects, perhaps secondary to microstructural alteration of the myelin sheaths of white matter with normal appearance.


REFERENCES

  1. Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563-76.

  2. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35.

  3. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am 2008;18:589-622.

  4. Simon JH, Li D, Traboulsee A. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am J Neuroradiol 2006;27:455-61.

  5. Ge Y. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 2006;27:1165-76.

  6. Pascual-Lozano AMM-B, MC, Boscá-Blasco I. Valero-Merino C, Coret-Ferrer F, Martí-Bonmatí L, Martínez-Granados B. Celda B, Casanova-Estruch B. Relación entre el volumen lesional cerebral total en resonancia magnética secuencia T2 y el daño neuroaxonal en la sustancia blanca aparentemente normal del tronco del encéfalo en la esclerosis múltiple remitente-recurrente. Rev Neurol 2007;45:468-73.

  7. Provenzale JM, Ortel TL. Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings. AJR Am J Roentgenol 1995;165:365-8.

  8. Provenzale J, Barboriak D, Allen N, Ortel T. Antiphospholipid antibodies: findings at arteriography. AJNR Am J Neuroradiol 1998;19:611-6.

  9. Ferreira S, D’Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 2005;44:434-42.

  10. Hincapié-Zapata MES-E JC, Pineda-Tamayo R, Anaya JM. Calidad de vida en esclerosis múltiple y otras enfermedades crónicas autoinmunes y no autoinmunes. Rev Neurol 2009;48:225-30.

  11. Hagmann P, Jonasson L, Maeder P, Thiran JP, Wedeen VJ, Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006;26 Suppl 1:S205-23.

  12. Oleaga L, Lafuente J. Monografia SERAM. Aprendiendo los fundamentos de la resonancia magnética. Primera ed. España: Médica Panamericana; 2007.

  13. Jellison BJ, Field AS, Medow J, Lazar M, Salamat MS, Alexander AL. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol 2004;25:356-69.

  14. Mukherjee P, Berman JI, Chung SW, Hess CP, Henry RG. Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings. AJNR Am J Neuroradiol 2008;29:632-41.

  15. Marco R, Federica A, Elisabetta P, Massimo F. Diffusion Tensor MR Imaging. Neuroimaging Clinics of North America 2009;19:37-43.

  16. Yu CS, Lin FC, Li KC. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 2006;27:1009-15.

  22. Lassmann H. The pathologic substrate of magnetic resonance alterations in multiple sclerosis. Neuroimaging Clin N Am 2008;18:563-76.

  23. Alonso A, Hernan MA. Temporal trends in the incidence of multiple sclerosis: a systematic review. Neurology 2008;71:129-35.

  24. Confavreux C, Vukusic S. The clinical epidemiology of multiple sclerosis. Neuroimaging Clin N Am 2008;18:589-622.

  25. Simon JH, Li D, Traboulsee A. Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers Consensus Guidelines. AJNR Am J Neuroradiol 2006;27:455-61.

  26. Ge Y. Multiple sclerosis: the role of MR imaging. AJNR Am J Neuroradiol 2006;27:1165-76.

  27. Pascual-Lozano AMM-B, MC, Boscá-Blasco I. Valero-Merino C, Coret-Ferrer F, Martí-Bonmatí L, Martínez-Granados B. Celda B, Casanova-Estruch B. Relación entre el volumen lesional cerebral total en resonancia magnética secuencia T2 y el daño neuroaxonal en la sustancia blanca aparentemente normal del tronco del encéfalo en la esclerosis múltiple remitente-recurrente. Rev Neurol 2007;45:468-73.

  28. Provenzale JM, Ortel TL. Anatomic distribution of venous thrombosis in patients with antiphospholipid antibody: imaging findings. AJR Am J Roentgenol 1995;165:365-8.

  29. Provenzale J, Barboriak D, Allen N, Ortel T. Antiphospholipid antibodies: findings at arteriography. AJNR Am J Neuroradiol 1998;19:611-6.

  30. Ferreira S, D’Cruz DP, Hughes GRV. Multiple sclerosis, neuropsychiatric lupus and antiphospholipid syndrome: where do we stand? Rheumatology 2005;44:434-42.

  31. Hincapié-Zapata MES-E JC, Pineda-Tamayo R, Anaya JM. Calidad de vida en esclerosis múltiple y otras enfermedades crónicas autoinmunes y no autoinmunes. Rev Neurol 2009;48:225-30.

  32. Hagmann P, Jonasson L, Maeder P, Thiran JP, Wedeen VJ, Meuli R. Understanding diffusion MR imaging techniques: from scalar diffusion-weighted imaging to diffusion tensor imaging and beyond. Radiographics 2006;26 Suppl 1:S205-23.

  33. Oleaga L, Lafuente J. Monografia SERAM. Aprendiendo los fundamentos de la resonancia magnética. Primera ed. España: Médica Panamericana; 2007.

  34. Jellison BJ, Field AS, Medow J, Lazar M, Salamat MS, Alexander AL. Diffusion tensor imaging of cerebral white matter: a pictorial review of physics, fiber tract anatomy, and tumor imaging patterns. AJNR Am J Neuroradiol 2004;25:356-69.

  35. Mukherjee P, Berman JI, Chung SW, Hess CP, Henry RG. Diffusion tensor MR imaging and fiber tractography: theoretic underpinnings. AJNR Am J Neuroradiol 2008;29:632-41.

  36. Marco R, Federica A, Elisabetta P, Massimo F. Diffusion Tensor MR Imaging. Neuroimaging Clinics of North America 2009;19:37-43.

  37. Yu CS, Lin FC, Li KC. Diffusion tensor imaging in the assessment of normal-appearing brain tissue damage in relapsing neuromyelitis optica. AJNR Am J Neuroradiol 2006;27:1009-15.




2020     |     www.medigraphic.com